StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
HRTXHERON THERAPEUTICS, INC. /DE/
stockpulse.co.kr
Nasdaq
$0.3100▲ 3.20%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $58.7MShares out 1.900M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

11
  • 3d agoRegular26.10.22 01:03
    4Ownership#●●●#●●●

    HERON THERAPEUTICS, INC. /DE/

    Ira Duarte, an insider at Heron Therapeutics, Inc., filed a Form 4 statement of changes in beneficial ownership of securities on October 19, 2026. This filing officially documents the changes in the insider's equity holdings.…more

    $0.3100+3.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 3d agoRegular26.10.22 01:01
    4Ownership

    HERON THERAPEUTICS, INC. /DE/

    William P. Forbes, an executive at Heron Therapeutics, Inc., filed an SEC Form 4 to report a change in his beneficial ownership of company securities as of October 19, 2026. This filing formalizes the changes in the executive's stock holdings.…more

    $0.3100+3.20%vs prev close
    View filingShare
  • 3d agoRegular26.10.22 01:00
    4Ownership

    HERON THERAPEUTICS, INC. /DE/

    Craig A. Collard, an executive at Heron Therapeutics, reported a change in his beneficial ownership of company securities as of October 19, 2026. This filing serves as a standard disclosure regarding the insider's stock holdings.…more

    $0.3100+3.20%vs prev close
    View filingShare

10 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.29After-hours26.09.30 06:07
    #●●●#●●●

    Heron Therapeutics Secures Exclusive U.S. Marketing Rights for New Products…more

    Heron Therapeutics has entered into a multi-product development and license agreement with Long Grove Pharmaceuticals to gain exclusive marketing rights in the U.S. The company will pay regulatory and sales-based milestone payments along with royalties under the agreement.…more

    $0.3100+3.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 7.27Pre-market26.07.27 21:30

    ●●●●●●●● ●●●●● ●●●●●●

    헤론 테라퓨틱스가 오는 8월 10일 컨퍼런스 콜을 통해 2026년 2분기 재무 실적과 주요 사업 성과를 발표할 예정이다. 투자자들은 이번 실적 발표를 통해 회사의 주요 제품군 성장세와 향후 경영 방향성을 확인할 수 있을 전망이다.…more

    $0.3100+3.20%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →